BackgroundEosinophils are key therapeutic targets in severe asthma that are suppressed by IL5 (mepolizumab) and IL5 receptor (benralizumab) blockade. The effect of IL5 pathway biologics on recently described homeostatic (hEOs) and inflammatory (iEOs) eosinophil subsets is unknown. We aimed to determine the relative impact of mepolizumab and benralizumab treatment on eosinophil subset and phenotype, and explore clinical associations of eosinophil subsets with severe asthma characteristics and treatment response.MethodsWe performed a cross‐sectional observational study of severe asthma (eosinophilic n = 32, non‐eosinophilic n = 23, mepolizumab‐treated n = 25), with longitudinal follow‐up of 30 eosinophilic participants at two timepoints (4–24 weeks, >24 weeks) post‐commencement of mepolizumab (n = 20) or benralizumab (n = 10). Blood hEOs and iEOs were measured by flow cytometry assessment of surface CD62L protein.ResultsiEO proportion was significantly lower in mepolizumab‐treated participants in both the cross‐sectional and longitudinal study. Mepolizumab and benralizumab depleted iEOs to a similar extent, however a significantly greater number of hEOs remained in mepolizumab participants at follow‐up. Greater iEO proportion correlated with poorer asthma control in eosinophilic but not non‐eosinophilic asthma. Higher residual iEO proportion correlated with poorer asthma control in mepolizumab‐treated individuals. Reduced blood eosinophil viability was observed in around half of mepolizumab‐treated participants, which was associated with significantly better asthma control and spirometry.ConclusionsMepolizumab depletes iEOs and reduces circulating eosinophil viability in severe asthma but preserves a residual population of circulatory hEOs. In contrast benralizumab depleted both iEOs and hEOs. Higher iEO abundance and eosinophil viability are associated with poorer clinical outcomes following mepolizumab‐treatment. Monitoring circulating eosinophil phenotype and viability may be useful to predict biologic treatment response in severe asthma.

中文翻译：

---

美泊利单抗可消除严重哮喘患者的炎症，但保留稳态嗜酸性粒细胞


背景嗜酸性粒细胞是严重哮喘的关键治疗靶点，可通过 IL5（美泊利单抗）和 IL5 受体（贝那利珠单抗）阻断来抑制。 IL5 通路生物制剂对最近描述的稳态 (hEO) 和炎症 (iEO) 嗜酸性粒细胞亚群的影响尚不清楚。我们的目的是确定美泊利珠单抗和贝那利珠单抗治疗对嗜酸性粒细胞亚群和表型的相对影响，并探讨嗜酸性粒细胞亚群与严重哮喘特征和治疗反应的临床关联。方法我们对严重哮喘（嗜酸性粒细胞n = 32，非嗜酸性粒细胞n = 23，美泊利单抗治疗n = 25），在开始使用美泊利单抗后的两个时间点（4-24 周，>24 周）对 30 名嗜酸性粒细胞参与者进行纵向随访（ n = 20) 或贝那利珠单抗 ( n = 10）。通过流式细胞术评估表面 CD62L 蛋白来测量血液 hEO 和 iEO。结果在横断面和纵向研究中，接受美泊利单抗治疗的参与者中 siEO 比例均显着降低。美泊利珠单抗和贝那利珠单抗对 iEO 的消耗程度相似，但在随访过程中，美泊利珠单抗参与者中仍然存在明显更多数量的 hEO。对于嗜酸性粒细胞性哮喘，iEO 比例越高，哮喘控制效果越差，但与非嗜酸性粒细胞性哮喘无关。在美泊利单抗治疗的个体中，较高的残留 iEO 比例与较差的哮喘控制相关。大约一半接受美泊利单抗治疗的参与者观察到血液嗜酸性粒细胞活力降低，这与显着更好的哮喘控制和肺活量测定相关。结论 美泊利单抗会消耗严重哮喘患者的 iEO 并降低循环嗜酸性粒细胞活力，但保留循环 hEO 的残留群体。相比之下，贝那利珠单抗耗尽了 iEO 和 hEO。较高的 iEO 丰度和嗜酸性粒细胞活力与美泊利单抗治疗后较差的临床结果相关。监测循环嗜酸性粒细胞表型和活力可能有助于预测严重哮喘的生物治疗反应。